Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-González, M.*
dc.contributor.authorGómez-Bernal, F.*
dc.contributor.authorQuevedo-Abeledo, J.C.*
dc.contributor.authorFernández-Cladera, Y.*
dc.contributor.authorGonzález-Rivero, A.F.*
dc.contributor.authorde Vera-González, A.*
dc.contributor.authorde la Rua-Figueroa, I.*
dc.contributor.authorLópez-Mejias, R.*
dc.contributor.authorDíaz-González, F.*
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel *
dc.contributor.authorFerraz-Amaro, I.*
dc.date.accessioned2025-09-09T11:23:41Z
dc.date.available2025-09-09T11:23:41Z
dc.date.issued2023
dc.identifier.citationGarcía-González M, Gómez-Bernal F, Quevedo-Abeledo JC, Fernández-Cladera Y, González-Rivero AF, de Vera-González A, et al. Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus. Frontiers in Immunology. 2023;14.
dc.identifier.issn1664-3224
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/64734727c0b3b138499891b5
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21520
dc.description.abstractBackground: To date a complete characterization of the components of the complement (C) pathways (CLassical, LEctin and ALternative) in patients with systemic lupus erythematosus (SLE) has not been performed. We aimed to assess the function of these three C cascades through functional assays and the measurement of individual C proteins. We then studied how they relate to clinical characteristics. Methods: New generation functional assays of the three pathways of the C system were assessed in 284 patients with SLE. Linear regression analysis was performed to study the relationship between the activity, severity, and damage of the disease and C system. Results: Lower values of the functional tests AL and LE were more frequent than those of the CL pathway. Clinical activity was not related to inferior values of C routes functional assays. The presence of increased DNA binding was negatively linked to all three C pathways and products, except for C1-inh and C3a which were positively related. Disease damage revealed a consistent positive, rather than a negative, relationship with pathways and C elements. Anti-ribosomes and anti-nucleosomes were the autoantibodies that showed a greater relationship with C activation, mainly due to the LE and CL pathways. Regarding antiphospholipid antibodies, the most related with C activation were IgG anti-?2GP, predominantly involving the AL pathway. Conclusion: Not only the CL route, but also the AL and LE are related to SLE features. C expression patterns are linked to disease profiles. While accrual damage was associated with higher functional tests of C pathways, anti-DNA, anti-ribosomes and anti-nucleosomes antibodies, were the ones that showed a higher relationship with C activation, mainly due to the LE and CL pathways.
dc.description.sponsorshipThis work was supported by a grant to IF-A from the Spanish Ministry of Health, Subdireccion General de Evaluacion y Fomento de la Investigacion, Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2013-2016 and by Fondo Europeo de Desarrollo Regional - FEDER - (Fondo de Investigaciones Sanitarias, FIS PI20/00084).
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshLupus Erythematosus, Systemic*
dc.subject.meshAutoantibodies *
dc.subject.meshAntibodies, Antiphospholipid *
dc.subject.meshAntibodies, Antinuclear *
dc.subject.meshComplement System Proteins *
dc.titleFull characterization of the three pathways of the complement system in patients with systemic lupus erythematosus
dc.typeArtigo
dc.authorsophosGarcía-González, M.; Gómez-Bernal, F.; Quevedo-Abeledo, J.C.; Fernández-Cladera, Y.; González-Rivero, A.F.; de Vera-González, A.; de la Rua-Figueroa, I.; López-Mejias, R.; Díaz-González, F.; González-Gay, M.Á.; Ferraz-Amaro, I.
dc.identifier.doi10.3389/fimmu.2023.1167055
dc.identifier.sophos64734727c0b3b138499891b5
dc.journal.titleFrontiers in Immunology*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Reumatoloxía
dc.relation.projectIDSpanish Ministry of Health, Subdireccion General de Evaluacion y Fomento de la Investigacion, Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion
dc.relation.projectIDFondo Europeo de Desarrollo Regional - FEDER - (Fondo de Investigaciones Sanitarias) [FIS PI20/00084]
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2023.1167055
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number14


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)